Trial Profile
A Phase Ib study of Trastuzumab emtansine plus S-1 or Capecitabine in patients with previously trastuzumab treated metastatic breast cancer
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 24 Jan 2018
Price :
$35
*
At a glance
- Drugs Trastuzumab emtansine (Primary) ; Capecitabine; Gimeracil/oteracil/tegafur
- Indications Advanced breast cancer
- Focus Adverse reactions
- Acronyms MARIA15-01
- 23 Jan 2018 Status changed from recruiting to completed.
- 28 Jul 2015 New trial record